Literature DB >> 22623216

Treatment and survival of osseous renal cell carcinoma metastases.

Andrea Evenski1, Shalini Ramasunder, William Fox, Varatharaj Mounasamy, H Thomas Temple.   

Abstract

BACKGROUND: Renal cell carcinoma is the seventh leading cause of cancer deaths. Studies have shown patients with solitary osseous metastases have a better prognosis; however, methods of resection are not well defined. The purpose of this study was to review factors associated with survival and assess the impact of wide versus intralesional management on function and disease-specific outcomes in patients with renal cell carcinoma metastases.
METHODS: Sixty-nine patients with 86 osseous renal cell metastases were reviewed. Potential factors associated with survival were evaluated with Kaplan-Meier curves. ANOVA was performed to compare means between groups.
RESULTS: One year survival for the group was 77% and 32.5% at 5 years. The absence of metastatic disease at presentation, nephrectomy, and pre-operative status were associated with improved survival. There was a lower rate of local recurrence with wide resection (5%) versus intralesional procedures (27%).
CONCLUSIONS: Improved pre-operative status, nephrectomy, and metachronous lesions had better overall survival. Wide resection results in decreased local recurrence and revision surgeries. However, it did not reliably predict improved survival. Our recommendation is for individual evaluation of each patient with osseous renal cell carcinoma metastases. Wide excision may be used for resectable lesions to prevent local progression and subsequent surgeries.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22623216     DOI: 10.1002/jso.23134

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  Obesity that makes kidney cancer more likely but helps fight it more strongly.

Authors:  Lin Li; Kamyar Kalantar-Zadeh
Journal:  J Natl Cancer Inst       Date:  2013-11-27       Impact factor: 13.506

Review 2.  Risk of chronic kidney disease after cancer nephrectomy.

Authors:  Lin Li; Wei Ling Lau; Connie M Rhee; Kevin Harley; Csaba P Kovesdy; John J Sim; Steve Jacobsen; Anthony Chang; Jaime Landman; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

Review 3.  [Metastatic disease in long bones : Review of surgical treatment options].

Authors:  Franz Liska; Philipp Schmitz; Norbert Harrasser; Peter Prodinger; Hans Rechl; Rüdiger von Eisenhart-Rothe
Journal:  Unfallchirurg       Date:  2018-01       Impact factor: 1.000

Review 4.  Treatment for long bone metastases based on a systematic literature review.

Authors:  Costantino Errani; Andreas F Mavrogenis; Luca Cevolani; Silvia Spinelli; Andrea Piccioli; Giulio Maccauro; Nicola Baldini; Davide Donati
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-09-20

5.  Is a Cephalomedullary Nail Durable Treatment for Patients With Metastatic Peritrochanteric Disease?

Authors:  David H Chafey; Valerae O Lewis; Robert L Satcher; Bryan S Moon; Patrick P Lin
Journal:  Clin Orthop Relat Res       Date:  2018-12       Impact factor: 4.176

Review 6.  Risk of chronic kidney disease after nephrectomy for renal cell carcinoma.

Authors:  Seung-Kwon Choi; Cheryn Song
Journal:  Korean J Urol       Date:  2014-10-10

7.  Surgery of non-spinal skeletal metastases in renal cell carcinoma: No effect of preoperative embolization?

Authors:  Maire Ratasvuori; Niko Sillanpää; Rikard Wedin; Clement Trovik; Bjarne H Hansen; Minna Laitinen
Journal:  Acta Orthop       Date:  2016-01-11       Impact factor: 3.717

8.  Intramedullary nailing vs modular megaprosthesis in extracapsular metastases of proximal femur: clinical outcomes and complication in a retrospective study.

Authors:  Raffaele Vitiello; Carlo Perisano; Tommaso Greco; Luigi Cianni; Chiara Polichetti; Rocco Maria Comodo; Ivan De Martino; Vincenzo La Vergata; Giulio Maccauro
Journal:  BMC Musculoskelet Disord       Date:  2022-09-13       Impact factor: 2.562

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.